ONSPC2014TARGET AUDIENCE OVERVIEW OF ACTIVITY Thus, the long-term care of patients with prostate cancer remains an important issue for researchers and clinicians alike, and oncology nurses play an integral role in the successful delivery of systemic anticancer therapy and in the maintenance of patient physical and psychosocial well-being. These video proceedings from the first part of a 6-part integrated CNE curriculum originally held at the 2014 ONS Annual Congress feature discussions with leading prostate cancer investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario. PURPOSE STATEMENT LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue FOR SUCCESSFUL COMPLETION CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Tomasz M Beer, MD Contracted Research: Astellas, Bristol-Myers Squibb Company, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Novartis Pharmaceuticals Corporation. Christie L Klisz, MSN, ANP-BC No real or apparent conflicts of interest to disclose. David I Quinn, MBBS, PhD Advisory Committee: Amgen Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Corporation, Genentech BioOncology, Janssen Pharmaceuticals Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Prometheus Laboratories Inc, Teva Oncology, Veridex LLC; Paid Research: Millennium: The Takeda Oncology Company, Sanofi; Other Remunerated Activities: Medivation Inc, Teva Oncology. Victoria Sinibaldi, MS, CRNP Advisory Committee and Speakers Bureau: Astellas. MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Astellas/Medivation Inc, Bayer HealthCare Pharmaceuticals and Dendreon Corporation. Hardware/Software Requirements: There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center. |